References
- Harris PN, Tambyah PA, Paterson DL. beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15:475–485.
- Korytny A, Riesenberg K, Saidel-Odes L, et al. Bloodstream infections caused by multi-drug resistant Proteus mirabilis: epidemiology, risk factors and impact of multi-drug resistance. Infect Dis (Lond). 2016;48:428–431.
- Cunha BA. The unexpected benefits of the national piperacillin/tazobactam shortage on antibiotic stewardship. Infect Dis (Lond). 2016;48:328–329.
- Public Health England. Voluntary surveillance of Escherichia coli bacteraemia in England, Wales and Nortern Ireland: 2008-2014. Health Protection Report. 2015;9:23–23.
- Fizpatrick JM, Biswas J, Edgeworth JD, et al. Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals. Clin Microbiol Infect. 2016;22:244–251.
- Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–1325.
- Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010;65(Suppl 3):iii25–iii33.